TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00621452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene rearrangement analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node biopsy
Description: Optional correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: genetically engineered lymphocyte therapy
Description: Receive genetically modified T cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study: NCT02634099

Intervention type: DEVICE
Group type: OTHER
Intervention: blood measurement
Description: Hemoglobin measurement

Intervention type: DEVICE
Group type: OTHER
Intervention: pulse co-oxymeter (SpHb)
Description: non invasive method of hemoglobin measurement

Intervention type: DEVICE
Group type: OTHER
Intervention: hemoCue
Description: non invasive method of hemoglobin measurement
Study: NCT03183830

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich Beetroot Juice
Description: The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
Study: NCT02477852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: preoperative treatment of spinal tuberculosis with Ethambutol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: preoperative treatment of spinal tuberculosis with Pyrazinamide
Study: NCT00289835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent
Description: Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment

Intervention type: DEVICE
Group type: OTHER
Intervention: Paclitaxel eluting stent
Description: Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
Study: NCT01204346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBT
Description: The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: less intensive and structured psychotherapeutic program
Study: NCT03584659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcomes
Description: Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
Study: NCT02763033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bob's Red Mill®
Description: Standard bone marrow transplant (BMT) diet + potato-based starch
Study: NCT03183830

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-deplete Beetroot Juice
Description: See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
Study: NCT02763033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Starch Placebo
Description: Standard bone marrow transplant (BMT) diet + corn-based starch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Starch Placebo
Description: Standard bone marrow transplant (BMT) diet + corn-based starch
Study: NCT02477852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: preoperative treatment of spinal tuberculosis with Pyrazinamide
Study: NCT04508920

Intervention type: OTHER
Intervention: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)
Description: Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization

Intervention type: OTHER
Intervention: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)
Description: Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
Study: NCT04130659

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MARIAL® + PPI (generic Omeprazole)
Description: MARIAL® administration: 1 stick twice daily after meals from day 1 to 28.~Omeprazole administration: 20 mg cps once daily from day 1 to day 28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI alone (generic omeprazole)
Description: Omeprazole administration: 20 mg cps once daily from day 1 to day 28

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARIAL® alone
Description: MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MARIAL® alone
Description: MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.
Study: NCT01715636

Intervention type: DRUG
Group type: OTHER
Intervention: Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg
Study: NCT00483093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
Study: NCT01129934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine-Promethazine
Description: administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Administration of intravenous morphine 0.1 mg/kg
Study: NCT00483093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
Study: NCT01246882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed-only feedback
Description: Feedback about walking speed will be provided 3 times per week.
Study: NCT01077063

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paracentesis
Description: surgical drainage of malignant ascites

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pleurx catheter
Description: take home catheter drainage system that the subject uses himself/herself as needed.
Study: NCT03994055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Diet will include foods rich in omega-3 fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble fiber
Description: Diet will include foods rich in soluble fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Diet will include foods rich in probiotics.
Study: NCT03858426

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00419549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl - trinitrate
Description: Transdermal Patch once only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valdecoxib
Description: Single parenteral administration
Study: NCT00619359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: fosaprepitant dimeglumine
Description: single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
Study: NCT03994055

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactose restriction
Description: Diet will be restricted to 5g lactose/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fiber restriction
Description: Diet will be restricted to 20g fiber/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fat restriction
Description: Diet will be restricted to 20% total energy intake
Study: NCT00979992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT00619359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Aprepitant
Description: Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: single IV dose of 32 mg of ondansetron on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: single IV dose of 32 mg of ondansetron on Day 1.
Study: NCT01780779

Intervention type: OTHER
Intervention: MRI
Description: MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment.

Intervention type: OTHER
Intervention: MRI
Description: MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment.
Study: NCT02617524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valve Medical Dedicated Sheath version 00
Description: The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
Study: NCT00725621

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
Study: NCT02595008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS
Description: Active treatment
Study: NCT01815112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
Study: NCT02740595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one time exposure to e-cig with nicotine
Description: one time exposure to e-cig vapor with nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one time exposure to e-cig without nicotine
Description: one time exposure to e-cig without nicotine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: one time exposure to empty e-cig
Description: one time exposure to empty e-cig (sham control
Study: NCT00507689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepatitis B Immunoglobulin (HBIg)
Description: HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
Study: NCT02671344

Intervention type: OTHER
Intervention: Determination of gene profiles using arrays semen
Description: Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.

Intervention type: OTHER
Intervention: Determination of gene profiles using arrays semen
Description: Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.

Intervention type: OTHER
Intervention: Determination of gene profiles using arrays semen
Description: Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
Study: NCT02100371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
Study: NCT00495417

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD01
Description: s.c. injection
Study: NCT01757405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIIa BI (rFVIIa BI)
Description: Administered approximately every 3 hours as an intravenous bolus injection on-demand
Study: NCT00495417

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AFFITOPE AD01 adjuvanted
Description: s.c. injection
Study: NCT01161563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin pamoate
Description: Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
Study: NCT00660439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist.
Study: NCT02957981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Counseling
Description: The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
Study: NCT02863900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cohort of BC of each subtypes
Study: NCT01807663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: healthy volonteers
Description: Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: healthy volonteers
Description: Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: healthy volonteers
Description: Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free breath monitoring
Description: Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free breath monitoring
Description: Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free breath monitoring
Description: Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
Study: NCT03953222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable real-time feedback device
Description: The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
Study: NCT04412018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Description: Icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days)
Study: NCT03894891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a chemotherapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a chemotherapy drug.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: IMRT is definitive treatment for head and neck cancer.
Study: NCT02750930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide
Description: Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-injector
Description: The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
Study: NCT01287494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
Study: NCT04349683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jinshuibao
Description: 6 capsules at a time, 3 times a day (tid).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules at a time, 3 times a day (tid).
Study: NCT01757405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIIa BI (rFVIIa BI)
Description: Administered as a single intravenous bolus injection on-demand
Study: NCT04343313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Half Moon TMVr System
Description: The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
Study: NCT00343291

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously